Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $159.27M |
| Gross Profit (TTM) | $46.86M |
| EBITDA | $199.18M |
| Operating Margin | -114.40% |
| Return on Equity | -929.00% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.52 |
| Book Value | $-0.11 |
| Price-to-Book | 170.66 |
| Price-to-Sales (TTM) | 3.38 |
| EV/Revenue | 5.68 |
| EV/EBITDA | 140.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $310.83M |
| Float | $304.17M |
| % Insiders | 8.86% |
| % Institutions | 55.44% |
Volatility is currently expanding
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
Nektar Therapeutics (NASDAQ:NKTR), Quantum-Si Inc (NASDAQ:QSI), and Pacific Biosciences of California Inc (NASDAQ:PACB) are all attracting elevated options activity today, as biotech stocks make volatile moves.
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PACB and any ticker you trade — then tracks every position and per-strategy win rate.
